



Bayer – Crop Science Division
PO Box 1582
Cambridge
CB1 0FE
United Kingdom

News Release

Chemicals Regulation Directorate lifts restriction for Bayer's Iblon® fungicide and adds barley to approved crops

Iblon® formulation and co-formulations can now be applied to wheat and barley grown in the same field in successive seasons.

Cambridge, November 11, 2025 – Bayer welcomed the decision by the Chemicals Regulation Directorate (CRD) to lift the restrictions on Bayer's Iblon® broad-spectrum fungicide. The product which contains the active ingredient isoflucypram can now be applied to wheat and barley grown in the same field in successive seasons. The decision follows the successful submission and evaluation of additional data submitted by Bayer and reflects the weight of evidence supporting the safety and efficacy of Iblon®. The CRD is part of Health & Safety Executive in the UK.

"This is good news for British growers, many of whom have come to appreciate the excellent broad-spectrum performance of Iblon®," said Nils Bauer, Managing Director of Bayer's Crop Science division in the UK. "The decision will allow growers to extend crop protection to successive crops grown in the same field and improve yield through extended crop greening, even where disease pressure is low. We hope soon to see this innovation also in the EU soon as until now Iblon® is only available to farmers in Great Britain and New Zealand."

The decision was communicated to Bayer at the same time that CRD also granted a label extension allowing for Vimoy® (Iblon®) to be used on barley, thereby expanding options for growers for the 2026 cropping season. Prior to October 2025, a maximum of 75g of Iblon® (isoflucypram) could be applied to a field every two years. At the minimum

supported dose of 50g active substance per ha, this effectively limited its use to one application every two years.

Growers can now utilise the broad-spectrum efficacy of products containing Iblon® such as Vimoy® (Iblon®), Jessico® Fusion (Iblon® and Inatreq™ active (fenpicoxamid)), Plaxium® (Iblon® + prothioconazole + fluopyram), Caley® (Iblon® + prothioconazole), Ipresso® (Iblon® + prothioconazole), Resilis® (Iblon® + prothioconazole), Milteo® (Iblon® + prothioconazole), Scorpio® (Iblon® + prothioconazole) and Vivalis® (Iblon® + prothioconazole) on approved crops grown in the same field in successive seasons.

Acknowledgements:

Vimoy® contains Iblon® (isoflucypram), Jessico® Fusion contains Iblon® and Inatreq™ active (fenpicoxamid), Plaxium® contains Iblon® and prothioconazole and fluopyram, Caley®, Ipresso®, Resilis®, Milteo®, Scorpio® and Vivalis® contain Iblon and prothioconazole.

Plaxium, Caley, Iblon, Ipresso, Jessico, Milteo, Resilis, Scorpio and Vimoy are registered trademarks of Bayer. Vivalis is a registered trademark of the Bayer group. Inatreq™ is a trademark of Corteva Agriscience and its affiliated companies.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contact for media inquiries:

Alexander Hennig, phone +44 7345 443625

Email: alexander.hennig@bayer.com

Find more information at www.bayer.co.uk

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.